<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596372</url>
  </required_header>
  <id_info>
    <org_study_id>18650</org_study_id>
    <secondary_id>2018-002561-19</secondary_id>
    <nct_id>NCT03596372</nct_id>
  </id_info>
  <brief_title>Study of BAY1834942 in Patients With Solid Tumors</brief_title>
  <official_title>An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed
      to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response
      profile of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6)
      antibody BAY1834942 in patients with advanced solid tumors known to have a prevalence for
      CEACAM6 expression.

      The study consists of dose escalation and a tumor type-specific expansion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the study are to evaluate and characterize the tolerability and
      safety profile of repeated doses of BAY1834942, and to characterize the pharmacokinetics of
      BAY1834942 after single dose.

      Secondary objectives are to evaluate the tumor response profile, pharmacodynamics,
      pharmacokinetics and immunogenicity after multiple doses of the drug.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Anticipated">November 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 40 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events</measure>
    <time_frame>Up to 40 months</time_frame>
    <description>Using the Common Terminology Criteria for Adverse Events (CTCAE) scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BAY1834942 after single dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after drug in Cycle 1 (cycle length is 21 days)</time_frame>
    <description>Maximum plasma concentration of drug after single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-504) of BAY1834942 after single dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after drug in Cycle 1 (cycle length is 21 days)</time_frame>
    <description>Area under the plasma concentration curve of drug from 0 to 504 hours after single dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-504),md of BAY1834942 after multiple doses</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h in Cycle 3 (cycle length is 21 days)</time_frame>
    <description>Area under the plasma concentration curve of drug from 0 to 504 hours after multiples doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,md of BAY1834942 after multiple doses</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h in Cycle 3 (cycle length is 21 days)</time_frame>
    <description>Maximum plasma concentration of drug after multiples doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 40 months</time_frame>
    <description>Percentage of patients whose best response to BAY1834942 is either a Complete response or Partial response, both defined according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte immune phenotyping</measure>
    <time_frame>Screening; 0 (pre-dose), 24, 168, 336 h after drug on Day 1 of Cycle 1 (cycle length is 21 days); 0 (pre-dose), 24, 168 h after drug on Day 1 of Cycle 2; 0 (pre-dose), 24 h after drug on Day 1 of Cycle 3; 0 h (pre-dose) on Day 1 of Cycles 4, 6 and 8</time_frame>
    <description>Whole blood flow cytometry (FACS) for characterization of blood leukocytes/ lymphocytes with regard to subpopulations, differentiation and activation before and under treatment in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEACAM6 receptor occupancy</measure>
    <time_frame>0 (pre-dose), 24, 168 and 336 h after drug on Day 1 of Cycle 1 (cycle length is 21 days); 0 h (pre-dose) on Day 1 of Cycle 2</time_frame>
    <description>Total and free CEACAM6 expression levels on blood granulocytes and monocytes as assessed by whole blood flow cytometry (FACS) using 2 different fluorescence-labeled anti-CEACAM6 antibodies either competing or not in CEACAM6 binding with BAY1834942 determined before and under treatment in all dose escalation cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>Screen.; 0 (pre-dose), 4, 24, 168, 336 h after drug on Day 1 of Cycle 1 (cycle length 21 days); 0 (pre-dose), 4, 24, 168 h after drug on Day 1 of Cycle 2; 0 (pre-dose), 4, 24 h after drug on Day 1 of Cycle 3; 0 h (pre-dose) on Day 1 of Cycles 4, 6 and 8</time_frame>
    <description>Total concentration of proinflammatory and immunostimulatory cytokines and of soluble interleukin 2 receptor in serum derived from whole blood taken before and under treatment in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ex vivo-stimulated cytokine secretion</measure>
    <time_frame>0 h (pre-dose) on Day 1 of Cycles 1, 2, 3, 4, 6 and 8 (cycle length is 21 days)</time_frame>
    <description>Total concentration of selected proinflammatory and immunostimulatory cytokines in culture plasma after 24 hour ex-vivo stimulation of whole blood taken before and under treatment in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of carcinoembryonic antigens (CEA; tumor marker) in serum</measure>
    <time_frame>0 h (pre-dose) on Day 1 of Cycles 1, 2, 3, 4, 6 and 8 (cycle length is 21 days)</time_frame>
    <description>Total concentration of CEA in serum derived from whole blood taken before and under treatment in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-drug antibodies</measure>
    <time_frame>Day 1 (pre-dose) of Cycles 1, 2, 3, 4, 6 and subsequent odd-numbered cycles (cycle length is 21 days); 1 Day of End of treatment; 1 Day of Safety Follow-up visit</time_frame>
    <description>Concentration in plasma</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced CEACAM6-expressing Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Patients with Solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:
Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion with patients having colorectal cancer:
Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Non-small-cell-lung cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion with patients having adeno Non-small-cell-lung cancer:
Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1834942</intervention_name>
    <description>Dose escalation:
Sequential dose levels
.
Dose expansion (except for low-dose expansion):
With maximum tolerated dose (MTD) identified in dose escalation part.</description>
    <arm_group_label>Low-dose expansion</arm_group_label>
    <arm_group_label>Patients with Colorectal cancer</arm_group_label>
    <arm_group_label>Patients with Gastric cancer</arm_group_label>
    <arm_group_label>Patients with Non-small-cell-lung cancer</arm_group_label>
    <arm_group_label>Patients with Solid tumors</arm_group_label>
    <other_name>Anti-CEACAM6 antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged â‰¥ 18 years

          -  Patients with histologically confirmed advanced/ metastatic solid tumors: Dose
             escalation: solid tumor types with a expression of CEACAM6 (gastric/ GEJ cancer,
             esophageal cancer, NSCLC, CRC, pancreatic cancer, cervical cancer, breast cancer,
             bladder cancer, head and neck squamous cell cancer, bile duct cancer); Dose expansion:
             advanced adeno NSCLC, CRC and gastric/ GEJ adenocarcinoma.

          -  ECOG-PS of 0 to 1.

          -  Adequate organ function (bone marrow, liver, kidneys).

          -  Adequate coagulation function.

          -  Adequate cardiac function

        Exclusion Criteria:

          -  Patients with active symptomatic or untreated brain metastases; possible exceptions
             for patients with treated asymptomatic central nervous system metastases

          -  Active autoimmune disease

          -  History or evidence of active pulmonary fibrosis, organizing pneumonia, or
             pneumonitis.

          -  Risk factors for bowel obstruction or bowel perforation

          -  History of cardiac disease

          -  Uncontrolled arterial hypertension despite optimal medical management

          -  Clinically relevant findings in electrocardiogram

          -  HIV infection

          -  Active HBV or HCV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital-University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-human</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>CEACAM6</keyword>
  <keyword>Checkpoint inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

